{
  "image_filename": "figure_p4_det_3_007.png",
  "image_path": "FlublokPI/extracted/figures/figure_p4_det_3_007.png",
  "image_type": "Figure",
  "page_number": 4,
  "block_id": "det_3_007",
  "claim_id": "claim_005",
  "claim": "Flublok (quadrivalent) was evaluated in the pivotal trial against Fluarix (quadrivalent standard-dose vaccine).",
  "supports_claim": true,
  "explanation": "Table showing PCR-confirmed influenza attack rates, relative risk (RR), and relative vaccine efficacy (rVE) for subjects receiving the study vaccine versus a comparator; footnotes indicate the comparator is the U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GSK. Evidence: Footnote stating Comparator = U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent. The image explicitly names Fluarix Quadrivalent as the comparator vaccine in the pivotal trial, which supports the claim.",
  "model_used": "o4-mini",
  "detailed_analysis": {
    "supports_claim": true,
    "image_description": "Table showing PCR-confirmed influenza attack rates, relative risk (RR), and relative vaccine efficacy (rVE) for subjects receiving the study vaccine versus a comparator; footnotes indicate the comparator is the U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent, manufactured by GSK.",
    "evidence_found": "Footnote stating Comparator = U.S.-licensed quadrivalent inactivated influenza vaccine, Fluarix Quadrivalent.",
    "reasoning": "The image explicitly names Fluarix Quadrivalent as the comparator vaccine in the pivotal trial, which supports the claim.",
    "confidence_notes": null
  }
}